Recent developments include analyst buy recommendations, clinical trial updates, and key licensing agreements that have influenced the company’s business trajectory in 2025.

• Sol-Gel Technologies was highlighted among 12 overlooked stocks delivering significant gains in 2025, indicating notable market interest [N2].
• HC Wainwright & Co. reiterated and maintained buy recommendations for Sol-Gel Technologies in late 2025, reflecting positive analyst sentiment [N3][N5].
• The company reported a widened Q3 loss in November 2025, signaling ongoing financial challenges [N4].
• Health Canada approved EPSOLAY, a key product, which was discussed in September 2025 as a significant regulatory milestone [N6].
• Sol-Gel signed a U.S. rights agreement with Mayne Pharma for EPSOLAY and TWYNEO in April 2025, receiving $16 million to extend cash runway and advance clinical trials [N8].
• Q1 2025 financial results showed increased R&D expenses, underscoring continued investment in product development [N7].
• Search interest in Sol-Gel Technologies spiked in March 2026, indicating heightened investor and market attention [N1].

The company has demonstrated revenue growth from licensing and collaboration agreements, including a significant $16 million deal with Mayne Pharma for U.S. rights to key products. Increased R&D investment supports ongoing clinical trials and product development, which could enhance the company’s product pipeline. Analyst coverage has been positive, with reiterated buy recommendations reflecting confidence in the company’s strategic direction. The company’s strong liquidity position as of December 31, 2025, provides operational runway to advance its clinical programs and business development efforts.

Sol-Gel Technologies continues to report net losses and has an accumulated deficit exceeding $237 million, indicating ongoing financial challenges. Management has expressed substantial doubt about the company’s ability to continue as a going concern without securing additional financing. The company’s reliance on successful clinical trial outcomes and regulatory approvals introduces execution risk. The absence of current entitlement to Israeli tax benefits and the need for capital raises to fund operations add to financial uncertainty. Market competition and potential delays in product commercialization could impact future revenue generation.

Sol-Gel Technologies' moat is primarily based on its proprietary dermatology product candidates and intellectual property, including licensed technologies and patents. The company’s collaborations and licensing agreements, such as the U.S. rights agreement with Mayne Pharma, provide market access and potential revenue streams. Its focus on specialized dermatology treatments and ongoing clinical development efforts contribute to its competitive positioning. However, as a development-stage pharmaceutical company, its moat is contingent on successful clinical outcomes, regulatory approvals, and the ability to commercialize its products effectively.

• Financial Sustainability Risk: The company has a history of net losses and an accumulated deficit of $237 million as of December 31, 2025. Management has noted substantial doubt about its ability to continue as a going concern without additional financing.
• Clinical and Regulatory Risk: Sol-Gel’s business depends on successful clinical trials and regulatory approvals for its dermatology products. Failure to achieve positive outcomes or regulatory clearance could adversely affect the company’s prospects.
• Dependence on Licensing and Collaboration Agreements: Revenue is significantly derived from licensing deals and collaborations, such as the agreement with Mayne Pharma. Changes or termination of these agreements could impact revenue streams.
• Market and Competitive Risk: The pharmaceutical dermatology market is competitive, and the company faces risks from competing products and technologies that could limit market penetration and revenue.

• Sol-Gel Technologies Ltd. is an Israeli company primarily engaged in research and development activities related to pharmaceutical products, with a focus on dermatology.
• The company operates as a single reportable segment, with consolidated net income used to measure performance.
• Revenue is generated from licensing agreements, royalties on net sales of licensed products, reimbursements, and cost-sharing of R&D expenses.
• In 2025, the company recognized $19.4 million in revenue, up from $11.5 million in 2024 and $1.55 million in 2023, reflecting growth in licensing and collaboration revenues.
• Research and development expenses were $22.8 million in 2025, increased from $17.8 million in 2024 and $23.5 million in 2023, indicating ongoing investment in clinical and preclinical trials.
• The company reported a net loss of $6.13 million in 2025, an improvement from losses of $10.6 million in 2024 and $27.2 million in 2023.
• Basic and diluted loss per share was -$2.19 in 2025, compared to -$3.79 in 2024 and -$10.01 in 2023, with share counts around 2.78 million shares (post 1-for-10 reverse split).
• Sol-Gel has licensing agreements including a terminated exclusive U.S. license with Galderma and a current license with Searchlight.
• In April 2025, Sol-Gel signed a product purchase agreement with Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO, receiving $16 million in two installments during 2025, fully recognized as revenue.
• The company has collaborative arrangements that include royalties and reimbursements, which affect revenue and R&D expense recognition.
• Geographically, revenue in 2025 was primarily from the United States ($16.7 million), with smaller amounts from Canada, Switzerland, Israel, and other regions.
• Sol-Gel's cash and cash equivalents as of December 31, 2025, were $11.03 million, with short-term investments of $12.97 million, total current assets of $26.97 million, and current liabilities of $6.17 million, resulting in a current ratio of 4.37 and a cash ratio of 3.89.
• The company has an accumulated deficit of $237 million as of December 31, 2025, and management has expressed substantial doubt about the company's ability to continue as a going concern without additional financing.
• The company is subject to Israeli tax laws and government programs, with no current entitlement to tax benefits under various Israeli Investment Law regimes but may qualify in the future.
• The company’s ordinary shares have one vote per share and have not declared dividends since inception.
• The executive chairman and controlling shareholder, Mori Arkin, has served as interim CEO since January 1, 2025, without compensation for this role.
• The company’s financial statements are prepared in U.S. dollars, which is the functional and presentation currency.
• Sol-Gel’s business model includes ongoing R&D, licensing, and collaboration agreements, with revenues recognized based on transfer of control and performance obligations.
• The company’s recent news includes analyst buy recommendations, clinical trial updates, and licensing agreements, reflecting active business development and investor interest.